TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Barclays PLC

Barclays PLC increased its stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 16.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,508 shares of the company’s stock after purchasing an additional 9,441 shares during the period. Barclays PLC owned 0.13% of TScan Therapeutics worth $206,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. abrdn plc boosted its stake in TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after purchasing an additional 512,049 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in TScan Therapeutics by 94.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company’s stock valued at $158,000 after acquiring an additional 15,441 shares during the period. Prudential Financial Inc. acquired a new stake in TScan Therapeutics during the 4th quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in TScan Therapeutics during the 4th quarter valued at approximately $32,000. Finally, Heck Capital Advisors LLC acquired a new stake in TScan Therapeutics during the 4th quarter valued at approximately $61,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

TCRX opened at $1.37 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The firm has a fifty day moving average price of $1.48 and a 200 day moving average price of $2.66. TScan Therapeutics, Inc. has a 1 year low of $1.02 and a 1 year high of $9.69. The stock has a market cap of $77.53 million, a P/E ratio of -1.29 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.62 million. Equities research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on TCRX shares. Wedbush restated an “outperform” rating and set a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Barclays decreased their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Morgan Stanley restated an “overweight” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, HC Wainwright decreased their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $8.50.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.